|
|
|
Volumn 62, Issue 6 Suppl CME, 2013, Pages
|
|
Integrating incretin-based therapy into type 2 diabetes management.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDIABETIC AGENT;
BIOLOGICAL MARKER;
DIPEPTIDYL PEPTIDASE IV INHIBITOR;
DRUG DERIVATIVE;
EXENDIN 4;
GLUCAGON LIKE PEPTIDE 1;
GLUCAGON LIKE PEPTIDE 1 RECEPTOR;
GLUCAGON RECEPTOR;
GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;
INCRETIN;
LIRAGLUTIDE;
PEPTIDE;
VENOM;
ARTICLE;
CLINICAL TRIAL (TOPIC);
COMPARATIVE STUDY;
DRUG ADMINISTRATION;
DRUG POTENTIATION;
HUMAN;
MEDICATION COMPLIANCE;
METABOLISM;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRACTICE GUIDELINE;
BIOLOGICAL MARKERS;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
DIPEPTIDYL-PEPTIDASE IV INHIBITORS;
DRUG ADMINISTRATION SCHEDULE;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
HYPOGLYCEMIC AGENTS;
INCRETINS;
MEDICATION ADHERENCE;
PEPTIDES;
PRACTICE GUIDELINES AS TOPIC;
RECEPTORS, GLUCAGON;
VENOMS;
|
|
EID: 84884191059
PISSN: None
EISSN: 15337294
Source Type: None
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
